LICITRA, LISA FRANCESCA LINDA
LICITRA, LISA FRANCESCA LINDA
Dipartimento di Oncologia ed Emato-Oncologia
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026 D. Rischin, A. R Hansen, E.E. W Cohen, M. Tahara, K. J Harrington, R. I Haddad, L. Licitra, H. Mehanna, R. L Ferris, P. Koralewski
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
2025 P. Mccoon, Y. Wang, Z. Lai, Q. Zhang, W. Li, S. Wildsmith, N. Morsli, R. Raja, N. Holoweckyj, J. Walker, M. De Los Reyes, R. Mesia, L. Licitra, R.L. Ferris, J. Fayette, D.P. Zandberg, L.L. Siu, R. Haddad
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 J. Fayette, L. Licitra, K. Harrington, R. Haddad, L.L. Siu, Y.-. Liu, M. Tahara, J.-. Machiels, D. Rischin, T.Y. Seiwert, R.L. Ferris, U. Keilholz, A. Psyrri, B. Keam, P. Bossi, R. Metcalf, C.-. Hsieh, P.M.J. Clement, P. Isaev, A. Mudunov, J. Dinis, A. Hoeben, S. Kasper, K. Klinghammer, M. Hwang, J. Blando, O. Serrano, D. Ruscica, R.B. Cohen
Epithelial head and neck cancer survival in Europe: Geographical variation, time trends and long term survival
2025 G. Gatta, S. Luttmann, A. Trama, S. Rossi, J. Galceran, K. Innos, M. Guevara, L. Licitra, D. Bennet, D. Redondo-Sanchez, R. Capocaccia
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose
2025 E. Ho, L. De Cecco, S.A. Eschrich, S. Cavalieri, G. Sedor, F. Hoebers, R.H. Brakenhoff, K. Scheckenbach, T. Poli, K. Yang, J.A. Scarborough, S. Nellore, S. Campbell, N. Woody, T. Chan, J. Miller, N. Silver, S. Koyfman, J. Bates, J.J. Caudell, M.W. Kattan, L. Licitra, J.F. Torres-Roca, J.G. Scott
Impact of head and neck cancer on the income of Italian employees
2025 A. Macciotta, A. Trama, A. Bernasconi, L. Licitra, R. Leombruni, M. Malisan, F. Ricceri, N. Zengarini, E. Farina
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study
2025 E. Colombo, S. Cavalieri, A. Vingiani, L. Agnelli, M. Duca, B. Paolini, F. Perrone, E. Tamborini, I. Capone, A. Piccolo, F. Caspani, C. Bergamini, S. Alfieri, C. Resteghini, I. Nuzzolese, A. Ottini, S. Buriolla, M. Salvetti, G. Calareso, M. Milione, G. Pruneri, L.D. Locati, L. Licitra
Gender Diversity in the Middle Management Matters: Examining Gender Metrics for Organizational and Sustainable Success
2025 A.D. Chiaramonte, C. Marazzi, D. Terruzzin, L. Anemoni, A. Mereghetti, E. Orlandi, L. Licitra
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer
2025 C. Even, K.J. Harrington, E. Massarelli, S. Laban, J. Fayette, M. Oliva, M. Klein Hesselink, S. Visscher, M.G. Fury, A.-. Wiekmeijer, L. Licitra, B. Melichar, L.A. Devriese, I. Brana, P. Jankowska, M. Posner, B. Glisson, A. Kong, L. Hooftman, C.J.M. Melief, R. Ferrarotto
Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide in head and neck cancer: the CONFRONT phase I-II trial
2025 M.C. Merlano, N. Denaro, M. Paccagnella, A. Abbona, D. Galizia, S. Alfieri, C. Bergamini, E. Orlandi, A.M. Merlotti, S. Bondi, L. Licitra, O. Garrone
Development, Validation, and Valuation of a Head and Neck Cancer-Specific Health Utility Instrument (HNC-8D): A Head and Neck Cancer International Group Collaborative Study
2025 J.R. De Almeida, J. Su, A. Alshenaiber, H. Noroozi, M. Buttner, D.P. Goldstein, A. Hansen, L.P. Kowalski, L. Licitra, H. Mehanna, C.W. Noel, A. Parmar, S. Porceddu, J. Ringash, S. Rogers, M.A. Dos Santos, C. Simon, M.-. Truong, W. Xu
Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
2025 C. Resteghini, B. Baujat, P. Bossi, A. Franchi, L. De Gabory, J. Halamkova, F. Haubner, J.A.U. Hardillo, M.A. Hermsen, N.A. Iacovelli, R. Maroldi, S. Mattheis, A. Moya-Plana, P. Nicolai, E. Orlandi, J. Thariat, A. Trama, M.W.M. Van Den Brekel, C.M.L. Van Herpen, B. Verillaud, E. Kinloch, L. Licitra, C. Even
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
2025 J.-. Machiels, Y. Tao, L. Licitra, B. Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P.F. Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, S. Laban, R. Greil, M. Burian, M. Hetnal, J.-. Delord, R. Mesia, M. Taberna, J. Waldron, C. Simon, V. Gregoire, K. Harrington, C.M. Black, J.M. Norquist, A. Wang, B. Gumuscu, B. Bidadiand, L.L. Siu
Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials
2025 C. Gurizzan, M. Cinquini, L. Legramandi, C. Resteghini, M. Siano, C. Bergamini, L. Lorini, D. Smussi, A. Paderno, L. Licitra, P. Bossi
Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer
2025 S. Cavalieri, R.H. Brakenhoff, C.R. Leemans, F. Hoebers, K. Scheckenbach, T.K. Hoffmann, D. Mattavelli, T. Poli, E. Orlandi, L. Licitra, L. De Cecco
The chemo-free approach for PDL1-positive platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma: Viable option or misguided myth?
2025 S. Cavalieri, N. Crippa, B. Lombardi Stocchetti, L. Licitra
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal canonccer
2025 M. Ferrari, F. Mularoni, D. Smussi, P. Gaudioso, P. Bonomo, J. Friborg, M.G. Ghi, V. Gregoire, K. Harrington, K. Hunter, R. Maroldi, R. Martino, R. Mesia, G. Peretti, A. Psyrri, A. Schindler, G. Succo, P. Szturz, I. Vilaseca, P. Nicolai, P. Bossi, J.P. Agarwal, M. Ansarin, A. Argiris, P. Balermpas, N.M.L. Battisti, E. Bellini, A. Bertolin, A.L.C. Carobbio, C.M. Chiesa-Estomba, B. Cirauqui, E. Crosetti, T.B. De Oliveira, A. Deganello, A. Dietz, J.G. Eriksen, A. Eskander, N. Fakhry, A. Falco, D. Farina, R. Ferrarotto, C. Franzese, S. Ghosh Laskar, W. Golusinski, E.Y. Hanna, J.C. Irish, N. Kiyota, L.P. Kowalski, S. Krishnan, N. Lee, C.R. Leemans, L. Licitra, L.D. Locati, J.-. Machiels, F. Marchi, D. Mattavelli, H. Mehanna, G. Mercante, N. Montalto, P. Morbini, B. O'Sullivan, M. Oliva, E. Orlandi, A. Paderno, V. Paleri, F. Pameijer, F. Perri, R. Persio, C. Piazza, Y. Pointreau, L. Presutti, M. Ravanelli, D. Rischin, J.P. Rodrigo, A. Ruaro, G. Sanguineti, C. Simon, L. Siu, A. Spreafico, G. Spriano, S. Taboni, U. Tassini, S. Tribius, M. Van Den Brekel, V. Vander Poorten, D. Viros Porcuna
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study
2025 J. Bourhis, L. Licitra, B. Burtness, A. Psyrri, R. Haddad, K. Harrington, E.E.W. Cohen, J.D. Schoenfeld
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC
2025 N.F. Saba, K. Harrington, L. Licitra, J.-. Machiels, C. He, T. Jew, V. Andrianov, R. Haddad
Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy
2025 P. Bossi, R. Gili, S. Calza, L. Licitra, M. Maddalo, A. Bacigalupo, L. Belgioia, J. Cacicedo, N. Facchinetti, A. Garcia Castano, M. Oliva, P. Bonomo, G. Sanguineti, P. Franco, A. Argiris, A. Psyrri, E. Orlandi